Is Geron Finally Onto Something?
Here's why biotech Geron is a prime buyout target.
3 Horrendous Health-Care Stocks This Week
What do Geron, Array BioPharma, and Pharmacyclics have in common? ASH presentations this week -- accompanied by double-digit drops.
3 Reasons Behind Geron's Rebound
Let’s take a look at three reasons Geron bounced back more than 200% in 2013, and how its industry peers -- Celgene, Novartis, and Incyte -- have been affected.